Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

TNFSF14 Protein (AA 1-239, partial) (GST tag)

TNFSF14 Origine: Humain Hôte: Escherichia coli (E. coli) Recombinant 90 % ELISA
N° du produit ABIN1047819
  • Antigène Voir toutes TNFSF14 Protéines
    TNFSF14 (Tumor Necrosis Factor (Ligand) Superfamily, Member 14 (TNFSF14))
    Type de proteíne
    Recombinant
    Attributs du protein
    AA 1-239, partial
    Origine
    • 26
    • 7
    • 2
    • 1
    Humain
    Source
    • 11
    • 9
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Escherichia coli (E. coli)
    Purification/Conjugué
    Cette TNFSF14 protéine est marqué à la GST tag.
    Application
    ELISA
    Séquence
    MEESVVRPSV FVVDGQTDIP FTRLGRSHRR QSCSVARVGL GLLLLLMGAG LAVQGWFLLQ LHWRLGEMVT RLPDGPAGSW EQLIQERRSH EVNPAAHLTG ANSSLTGSGG PLLWETQLGL AFLRGLSYHD GALVVTKAGY YYIYSKVQLG GVGCPLGLAS TITHGLYKRT PRYPEELELL VSQQSPCGRA TSSSRVWWDS SFLGGVVHLE AGEKVVVRVL DERLVRLRDG TRSYFGAFM
    Attributs du produit
    Please inquire if you are interested in this recombinant protein expressed in E. coli, mammalien cells or by baculovirus infection. Be aware about differences in price and lead time.
    Pureté
    90 %
    Top Product
    Discover our top product TNFSF14 Protéine
  • Commentaires

    The yeast protein expression system is the most economical and efficient eukaryotic system for secretion and intracellular expression. A protein expressed by the mammalian cell system is of very high-quality and close to the natural protein. But the low expression level, the high cost of medium and the culture conditions restrict the promotion of mammalian cell expression systems. The yeast protein expression system serve as a eukaryotic system integrate the advantages of the mammalian cell expression system. A protein expressed by yeast system could be modificated such as glycosylation, acylation, phosphorylation and so on to ensure the native protein conformation. It can be used to produce protein material with high added value that is very close to the natural protein. Our proteins produced by yeast expression system has been used as raw materials for downstream preparation of monoclonal antibodies.

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Concentration
    0.2-2 mg/mL
    Buffer
    Tris-based buffer, 50 % glycerol
    Conseil sur la manipulation
    Repeated freezing and thawing is not recommended. Store working aliquots at 4 °C for up to one week
    Stock
    -20 °C
    Stockage commentaire
    Store at -20 °C for extended storage, conserve at -20 °C or -80 °C
  • Harrop, McDonnell, Brigham-Burke, Lyn, Minton, Tan, Dede, Spampanato, Silverman, Hensley, DiPrinzio, Emery, Deen, Eichman, Chabot-Fletcher, Truneh, Young: "Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth." dans: The Journal of biological chemistry, Vol. 273, Issue 42, pp. 27548-56, (1998) (PubMed).

    Mauri, Ebner, Montgomery, Kochel, Cheung, Yu, Ruben, Murphy, Eisenberg, Cohen, Spear, Ware: "LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator." dans: Immunity, Vol. 8, Issue 1, pp. 21-30, (1998) (PubMed).

  • Antigène
    TNFSF14 (Tumor Necrosis Factor (Ligand) Superfamily, Member 14 (TNFSF14))
    Autre désignation
    Tumor necrosis factor ligand superfamily member 14 protein (TNFSF14 Produits)
    Synonymes
    TNFSF14 Protein, CD258 Protein, HVEML Protein, LIGHT Protein, LTg Protein, TR2 Protein, HVEM-L Protein, Ly113 Protein, TNF superfamily member 14 Protein, tumor necrosis factor (ligand) superfamily, member 14 Protein, TNFSF14 Protein, Tnfsf14 Protein
    Sujet
    Cytokine that binds to TNFRSF3/LTBR. Binding to the decoy receptor TNFRSF6B modulates its effects. Activates NFKB, stimulates the proliferation of T-cells, and inhibits growth of the adenocarcinoma HT-29. Acts as a receptor for Herpes simplex virus.
    Poids moléculaire
    53.6 kD
    UniProt
    O43557
    Pathways
    Cancer Immune Checkpoints
Vous êtes ici:
Support technique